Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 9, 2001

View Archived Issues

AxyS describes new serine protease inhibitor design technology

Ascorbic acid enhances arsenic trioxide potency in MM cells

Replagal receives European approval for Fabry's disease

Graffinity Pharmaceutical Design and Biosearch Italia form drug discovery alliance

Data from Metformin GR phase II trial reported by DepoMed

Lexicon Genetics and Immunex enter drug target validation agreement

Novel imino sugar inhibits HBV DNA replication without affecting DNA polymerase function

Lorus Therapeutics expands Virulizin clinical trial for pancreatic cancer

MedImmune begins Vitaxin phase I trials for rheumatoid arthritis

Guanfacine improves tic disorders and ADHD in children

Baxter to acquire Asta Medica Oncology

Bayer withdraws cerivastatin worldwide

FDA approves PEG-Intron for use with Rebetol

Trimeris and Array Biopharma sign drug discovery agreement

Sustained-release preparations of hypoglycemic drugs described by Ajinomoto

BVdU reported to be useful for inhibiting the growth of hyperproliferative cells

Cyclin-dependent kinase inhibitors identified by Bristol-Myers Squibb

Kyowa Hakko patents new compounds for treatment of urinary incontinence

Smooth muscle-relaxing agents reported by Kissei

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
In 2025, science’s biggest story was political
BioWorld
In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...
Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis
BioWorld Science
Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...